Navigation Links
Anesiva Receives NASDAQ Listing Compliance Notice
Date:12/8/2009

tion in multiple indications for site-specific, acute and chronic, moderate-to-severe pain.

Forward-Looking Statements

Except for historical information, this press release may be deemed to contain "forward-looking" statements. Words such as "may," "seek," "will," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include statements regarding expectations as to compliance with Nasdaq's listing standards, expectations as to forecasts of product development and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from those referred to in the forward-looking statements. Such risks include, but are not limited to, the risk that Anesiva otherwise fails to comply with the continued listing requirements of The NASDAQ Global Market or any other NASDAQ market; as well as the risk of whether certain market segments grow as anticipated; clinical trial results; the competitive environment in the biotechnology industry; and whether Anesiva can successfully develop new products and the degree to which these gain market acceptance as well as other risks detailed from time to time in Anesiva's filings with the Securities and Exchange Commission (the "SEC"), including Anesiva's most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2008, its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K as filed with the SEC. Anesiva expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Anesiva Stockholders Approved Merger With Arcion Therapeutics but Merger Remains Contingent on Other Closing Conditions
2. Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger
3. Anesiva Announces Going Concern Opinion and Nasdaq Notice
4. Anesiva Announces Planned Rights Offering
5. Anesiva Announces May 22, 2008 Presentation at Citi Investment Research Global HealthCare Conference
6. Anesiva and Sigma-Tau Announce Exclusive Marketing and Distribution Agreement for Zingo(TM) in Six European Countries
7. Anesiva Announces Hiring of Sales Force for FDA-Approved Product Zingo(TM)
8. Anesiva Announces Upcoming Webcasts and Conference Participation
9. Anesiva to Announce Third Quarter 2007 Financial Results and Host Webcast Conference Call on November 1, 2007
10. Anesiva to Present at BIO InvestorForum on October 11, 2007
11. Anesiva to Unveil Zingo(TM) Commercialization Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 It is said ... proved this to be true as a product sponsor ... in Las Vegas this past June. , Lash Affair ... and overall success of the eyelash industry through collaboration so ... proud to have supported NEESA ’s event. Lash Affair’s ...
(Date:7/30/2014)... mutation linked to obesity respond differently to pictures of ... not have the genetic mutation, according to a new ... Clinical Endocrinology & Metabolism ( JCEM ). , ... results from a combination of eating too much, getting ... of appetizing foods that are high in calories can ...
(Date:7/30/2014)... Texas (PRWEB) July 30, 2014 The ... (2013-18)” provides an insight into the market dynamics and ... report covers the actual and forecasted market sizing of ... various factors fuelling the demand of the same. It ... segment and major players in the market. Further, the ...
(Date:7/30/2014)... July 30, 2014 Dialogic ... today announced that DollarPhone, the largest privately owned ... the Dialogic® ControlSwitch™ softswitch to offer ... number portability (LNP) to both its wholesale and ... ControlSwitch is able to power DollarPhone’s network infrastructure, ...
(Date:7/30/2014)... HealthDay Reporter , TUESDAY, July ... might set the stage for harmful health habits, including eating ... conducted from 1982 to 2012 also found a link between ... younger a woman was when she started her first diet, ... control behaviors -- like vomiting or laxative misuse," said study ...
Breaking Medicine News(10 mins):Health News:Lash Affair Launches a New Product as Sponsor of the First U.S. Lash Extension Competition 2Health News:Brain response to appetizing food cues varies among obese people 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 3Health News:DollarPhone Expands Prepaid and Wholesale Offerings With Enhanced Dialogic ControlSwitch 2Health News:DollarPhone Expands Prepaid and Wholesale Offerings With Enhanced Dialogic ControlSwitch 3Health News:Dieting at Young Age Often Backfires, Study Says 2Health News:Dieting at Young Age Often Backfires, Study Says 3
... analysis of records of pancreatic surgery during the last ... pancreatic cancer surgeon// Charles J. Yeo, M.D., Samuel D. ... College of Thomas Jefferson University and Thomas Jefferson University ... his colleagues have revealed that contrary to what many ...
... major intestinal surgery, including stomach reduction for obesity, may ... results of the study have been published in the ... findings on three patients with increasingly poor eyesight or ... the space of a year. None of the patients ...
... A number of Canadians are more obese ... smoking less, according to a new national health survey// . ... Canada, on Tuesday, revealed that there was an underestimation ... by approximately nine per cent. The survey also indicated ...
... that a man is very critical and is suspected to have ... in a Shenzhen hospital. It is very evident that the virus ... Health Protection said that the victim lives in Shenzhen and is ... residing in Shenzhen. He fell ill after he visited a wet ...
... Families who fear the transfer of genetic diseases to their progeny ... a major NHS bank of babies' stem cells//. ,Stem ... to treat diseases such as leukemia. However cord blood banking has ... public as well as clinicians, wherein blood is taken from the ...
... warn the number of New Zealanders who take party pills ... authorities argued taking// party pills escape people from taking drugs. ... used the pill atleast once – says researchers commissioned by ... physical and psychological parts such as sleeplessness, loss of appetite, ...
Cached Medicine News:Health News:Pancreatic Cancer Surgery Successful in 80-Year-Olds 2Health News:Pancreatic Cancer Surgery Successful in 80-Year-Olds 3Health News:Incidence Of Smoking Less, Obesity More, in Canada: StatsCan 2Health News:Bank of Stem Cells to Give Hope to Sick Children 2
(Date:7/30/2014)... , July 30, 2014   Bluegrass ... focused on innovating lifesaving devices and methods for ... million in Series A financing, which was led ... from the deal will allow Bluegrass Vascular to ... Catheter System, enhance manufacturing capabilities, and proceed with ...
(Date:7/30/2014)... 30, 2014  PDL BioPharma, Inc. (PDL) (NASDAQ: ... participate in the Jefferies 2014 Boston Healthcare Summit next ... will occur on August 6, 2014 and will not ... PDL BioPharma manages a portfolio of patents and ... antibody humanization patents and license agreements with various biotechnology ...
(Date:7/30/2014)... , 30. Juli 2014 Die ... führender Anbieter im Bereich Atemtherapie- und Druckzonenprodukte, ... Landgerichts München in Deutschland anfechten werden. Dieses ... Masken ein Patent von ResMed verletze. Apex ... wichtigen Ländern gegen verschiedene Patente von ResMed ...
Breaking Medicine Technology:Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3
... Near-Complete Mitigation of Choroidal,Neovascularization (CNV) in an AMD ... Lpath, Inc. ,the category leader in therapeutic agents ... standard animal,model of human age-related macular degeneration (AMD). ... meeting of the,Association of Research in Vision and ...
... of SEROQUEL XR--, WILMINGTON, Del., May 22, ... analyses from a large-scale,study that investigated the ... a once-daily medicine for the,treatment of schizophrenia ... annual meeting of the American Psychiatric Association,(APA). ...
Cached Medicine Technology:Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 2Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 3Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 4New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 2New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 3New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 4New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 5New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 6New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 7New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 8New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 9
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Nucleus manipulator used during phacoemulsification. Used to break-up the nuclues within the capsular bag during two-handed phaco techniques. Blunt round tip, angled 40 degrees, 11mm from tip. Tip an...
... effective upgrade path that allows users to ... modularity. The potential to combine two units ... a single stimulating coil. The ability to ... the power level of each Magstim 200 ...
... The Magstim Model 200 uses a ... otherwise inaccessible nerves. World market leader in ... developed by the University of Sheffield in ... cortical hemispheric and peripheral stimulation. Our best ...
Medicine Products: